Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
Garrett W. Rhyasen(AstraZeneca (United States)), Daniel T. Starczynowski(Cincinnati Children's Hospital Medical Center), Craig J. Thomas(National Institutes of Health), Carmela Rigolino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Mark Wunderlich(Cincinnati Children's Hospital Medical Center), Maria Cuzzola(University of Messina), Lyndsey Bolanos(Cincinnati Children's Hospital Medical Center), Noel Southall(National Institutes of Health), Jing Fang(Wuhan Puai Hospital), Rajarshi Guha(Vertex Pharmaceuticals (United States)), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Esther N. Oliva(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Jaroslaw P. Maciejewski(Cleveland Clinic), Levi J. Beverly(University of Louisville), Andrés Jerez(Cleveland Clinic), Jonathan M. Keller(National Institutes of Health), James C. Mulloy(Cincinnati Children's Hospital Medical Center), Lesley Mathews(National Institutes of Health), Marc Ferrer(National Institute of Biomedical Innovation, Health and Nutrition)
Cited by 203
Related Papers
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|653
Increased demand for NAD+ relative to ATP drives aerobic glycolysis
|Molecular Cell|2020|561